← Back to Categories AI News

Corporate Governance

13 articles

Polaris Pharmaceuticals-KY Announces Remuneration Committee Member Appointments

Polaris Pharmaceuticals-KY (6550) announced on May 15, 2026, that its board of directors has resolved to appoint new members to the Remuneration Committee. This change follows the comprehensive re-election of directors, including independent directors, at the company's 2026 annual general meeting. The previous committee members' terms have expired. The newly appointed members are Zhao Yingcheng, Di Shijie (Associate Professor at the University of Hong Kong), and Zhang Zhigang (CEO of Zhongen Biomedical). The effective date for the new appointments is May 15, 2026.

Polaris Pharmaceuticals-KY Announces Audit Committee Member Changes

Polaris Pharmaceuticals-KY (6550) announced changes to its Audit Committee members on May 15, 115 (2026). The changes are due to the full re-election of directors, including independent directors, at the company's 2026 Annual General Meeting. The previous term for the independent directors was from September 26, 112 (2023) to June 11, 115 (2026). Zhao Ying-Cheng, an independent director, has been re-appointed. New independent directors appointed are Zhang Yi-Fang (Vice President of Mackay Taitung Branch), Zhang Zhi-Gang (CEO of Zhongen Biomedical), and Di Shi-Jie (Associate Professor at the University of Hong Kong). Zhao Ying-Cheng's brief biography is listed as former TSMC Plant Manager.

Polaris Pharmaceuticals-KY Announces Re-election of Chairman

Polaris Pharmaceuticals-KY (stock code 6550) announced on May 15, 2026, that its Board of Directors has re-elected Chen Xian-Zhe as Chairman. The re-election is a result of the expiration of his previous term. The company stated that this event is considered to have a significant impact on shareholder equity or stock prices.

Polaris Pharmaceuticals-KY: Shareholders Approve Lifting of Director Non-Competition Restrictions

Polaris Pharmaceuticals-KY announced that its shareholders' meeting held on May 15, 2026, approved the resolution to lift the non-competition restrictions for its new directors. The approved activities include investing in or operating businesses that are the same as or similar to the company's business scope. This waiver is effective from May 15, 2026, until the directors' term concludes. The decision was made in accordance with Article 209 of the Company Act.

Polaris Pharmaceuticals-KY (6550) Announces Board Re-election at Annual General Meeting

Polaris Pharmaceuticals-KY (6550) announced on May 15, 115 (2026) that its 115th annual general meeting of shareholders resulted in the full re-election of its board of directors, including independent directors. This change is due to the expiration of the current term. The new board includes re-elected members such as Chen Xian-Zhe, who will continue as Chairman, and new appointments like Zhou Hong-Jie, who holds a PhD in Chemistry and Chemical Biology from Harvard University. Other new directors and independent directors were also elected. The previous term ran from September 26, 112 (2023) to June 11, 115 (2026).

CPC Corporation (1314): Announcement of Corporate Director Representative Change and Board Turnover at Subsidiary

CPC Corporation (1314) announced that its corporate director representative at its important subsidiary, Dingyue Development Co., Ltd., has resigned due to personal reasons. The former representative, Zhou Zhiming, who also served as Chairman of China Engineering Consultants, Inc., has stepped down. A new representative is pending appointment. This change, effective May 19, 115 (2026), represents a one-third change in the board for the current term.

Yuanta Financial Holding: Yuanta Savings Bank (Philippines) Reappoints Audit Committee Members

Yuanta Financial Holding (2885) announced on May 15, 2026, that its subsidiary, Yuanta Savings Bank (Philippines), has reappointed its Audit Committee members. The reappointment is due to the expiration of their terms. Senen L. Matoto and Arturo E. Manuel, Jr. will continue as Independent Directors, and Hsiao Chi-Liang will continue as Director. The new term commences on May 15, 2026.

Yuan Ta Financial Holding: Re-appointment of Directors for Yuan Ta Savings Bank (Philippines)

Yuan Ta Financial Holding announced on May 15, 2025, that its subsidiary, Yuan Ta Savings Bank (Philippines), has re-appointed its directors and independent directors. The individuals, including Directors Wu Jing-Tang, Lei Zhen-Na, and Xiao Ji-Liang, and Independent Directors Senen L. Matoto and Arturo E. Manuel, Jr., were re-appointed as their previous terms expired on May 14, 2025. The new terms are effective from May 15, 2025. This change is due to term expiration and does not involve a significant shift in board composition.

Zhaoden-KY (4190) Announces Change in Accounting Firm Due to Internal Rotation

Zhaoden-KY (4190) announced on May 15, 2026, that it is changing its accounting firm due to an internal rotation policy at the accounting firm. The board approved the change on the same day. The previous accounting firm was Deloitte & Touche, with auditors Liu Yi-ching and Huang Hsiu-chun. The new accounting firm is also Deloitte & Touche, with auditors Liu Yi-ching and Tsai Yu-ling. This change complies with Article 7 of the relevant regulations. The company stated that there were no significant adjustments or recommendations from the previous auditor that it disagreed with.

[Synergy] Announces Shareholder Meeting Resolution: Waiver of Non-Compete Restrictions for New Directors

Synergy announced that its major subsidiary, Sung Da Optoelectronics Technology Co., Ltd., held a shareholder meeting on April 30, 115. The meeting approved the waiver of non-compete restrictions for newly appointed directors, including Lin Yishan, Wang Cao Zhengxiong, and Chen Xiaoguang, allowing them to engage in similar business activities during their tenure.